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Abstract
Rituximab‐containing induction followed by autologous stem cell trans-
plantation (ASCT) is the standard first‐line treatment for young mantle cell
lymphoma patients. However, most patients relapse after ASCT. We inves-
tigated in a randomised phase II study the outcome of a chemo‐immuno
regimen and ASCT with or without maintenance therapy with bortezomib.
Induction consisted of three cycles R‐CHOP (rituximab, cyclophosphamide,
doxorubicin, vincristine, prednisone), two cycles high‐dose cytarabine,
BEAM (carmustine, etoposide, cytarabine, melphalan) and ASCT. Patients
responding were randomised between bortezomib maintenance (1·3 mg/m2
intravenously once every 2 weeks, for 2 years) and observation. Of 135 eli-
gible patients, 115 (85%) proceeded to ASCT, 60 (44%) were randomised.
With a median follow‐up of 77·5 months for patients still alive, 5‐year
event‐free survival (EFS) was 51% (95% CI 42–59%); 5‐year overall survival
(OS) was 73% (95% CI 65–80%). The median follow‐up of randomised
patients still alive was 71·5 months. Patients with bortezomib maintenance
had a 5‐year EFS of 63% (95% CI 44–78%) and 5‐year OS of 90% (95%
CI 72–97%). The patients randomised to observation had 5‐year PFS of
60% (95% CI, 40–75%) and OS of 90% (95% CI 72–97%). In conclusion,
in this phase II study we found no indication of a positive effect of borte-
zomib maintenance after ASCT.
Keywords: bortezomib, cytarabine, maintenance therapy, Mantle cell lym-
phoma, phase II trial, randomised.
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The prognosis of mantle cell lymphoma (MCL) has
improved considerably with the introduction of rituximab,
high‐dose cytarabine and autologous stem cell transplanta-
tion (ASCT) in first‐line treatment (Dreyling et al., 2017).
The conditioning regimen may consist of BEAM (carmustine,
etoposide, cytarabine, melphalan) or total‐body irradiation in
combination with chemotherapy (Hoster et al., 2016).
The Dutch Haematology‐Oncology Cooperative Group
(HOVON) has previously investigated the role of three cycles
of R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vin-
cristine and prednisone) followed in responding patients by
one cycle of high‐dose cytarabine (HD‐Ara‐C) and ASCT in
MCL (van’t Veer et al., 2009). In this phase II study
(HOVON 45), the 4‐year progression‐free survival (PFS) was
44%, and the 4‐year overall survival (OS) was 66%. In order
to increase the PFS and OS we designed a subsequent study
(HOVON 75) in which we changed three aspects: first, HD‐
Ara‐C was given to all patients, irrespective of the response
to R‐CHOP. Second, we added a second cycle of HD‐Ara‐C
to induction therapy based on positive results from studies
of the Nordic group (Geisler et al., 2008). Finally, to explore
if bortezomib maintenance therapy after ASCT could be of
benefit, we randomised transplanted patients to bortezomib
maintenance or no further treatment. Bortezomib was chosen
for this purpose based on its efficacy in relapsed/refractory
MCL. A response rate of about 45% with a median duration
of about 12 months was achieved in several clinical studies.
Based on these favourable results, bortezomib received
approval for the treatment of relapsed/refractory MCL
(Fisher et al., 2006; Goy et al., 2009; Kane et al., 2007; Zin-
zani et al., 2013).
Patients and methods
Eligibility
Patients 18–65 years with newly‐diagnosed MCL, Ann Arbor
stage II to IV, with WHO performance status 0 to 2 and
measurable disease were eligible for study participation. Pri-
mary diagnosis was made on a representative lymph node or
extranodal site biopsy sample and included histological and
complete immunohistochemical assessment according to the
criteria of the WHO classification (WHO 2008, as valid dur-
ing inclusion and largely unchanged in the present WHO
classification 2016). Confirmation of the diagnosis by central
pathology review was part of the quality assessment and per-
formed by two hematopathologists (DDJ, REK) according to
routine procedures by the HOVON Pathology Facility (www.
hovon.nl). Exclusion criteria were creatinine clearance
<50 ml/min, CNS involvement, HIV or hepatitis B or C pos-
itivity, peripheral neuropathy >grade 2, other active malig-
nancy and other serious medical conditions that could
interfere with study treatment.
Patients who completed BEAM consolidation with ASCT,
with recovery of neutrophils to >0·5 9 109/l and platelets to
>80 9 109/l, without neuropathy grade 2 or more, were eli-
gible for randomisation between bortezomib maintenance
and no further treatment.
Staging procedures and response monitoring
Staging workup consisted of standard cervical, thoracic and
abdominal CT scans. Bone marrow involvement was assessed
by cytomorphologic and immunologic examination of bone
marrow aspirate and histology of bone marrow trephine. If
clinically indicated, endoscopy or other investigations for
extranodal localisations were performed. Response was evalu-
ated according to the 1999 Cheson criteria (Cheson et al.,
1999). Response evaluation was performed after the 2nd HD‐
Ara‐C cycle and after ASCT before randomisation. During
the maintenance phase, patients were evaluated with CT‐scan
and bone marrow analysis at 3, 6, 12, 18 and 24 months.
During further follow‐up, patients were evaluated every
6 months, and at the moment of relapse or progression.
Study design
This investigator‐initiated, multicentre, phase II trial was
designed, performed and sponsored by HOVON, and was
conducted in 15 centres in the Netherlands. All patients were
registered and randomised via the internet through TOP
(Trial Online Process; https://www.hdc.hovon.nl/top/logon.a
sp). No stratification factors according to baseline character-
istics were defined.
The treatment schedule consisted of three cycles of
R‐CHOP21 (rituximab 375 mg/m2 day 1, cyclophosphamide
750 mg/m2 day 1, doxorubicin 50 mg/m2 day 1, vincristine
1·4 mg/m2 day 1 (max 2 mg), all intravenous (IV), and
prednisone 100 mg day 1–5 orally), followed by two cycles
of cytarabine [2 9 2 g/m2 IV day 1–4 (every 12 hours) in a
3‐hours saline infusion] and rituximab (375 mg/m2, IV) on
day 11 aiming at in vivo purging of CD20 + mantle cells
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during mobilisation. One of the cytarabine cycles was used
for stem cell mobilisation with G‐CSF to be started at day 8.
A minimum of 3 9 106 CD34 + cells/kg was considered suf-
ficient for transplantation. Patients in partial (PR) or com-
plete remission (CR) after the second cycle of HD‐Ara‐C
continued with ASCT after BEAM conditioning (carmustine
300 mg/m2 day −7, cytarabine 2 9 100 mg/m2 day −6 to
−3, etoposide 2 9 100 mg/m2 day −6 to −3 and melphalan
140 mg/m2 day −2, IV). All other patients went off protocol.
Patients with a PR or CR after ASCT with a neutrophil
count >0·5 9 109/l and platelets >80 9 109/l were ran-
domised (1:1) between bortezomib and no further treatment.
Bortezomib 1·3 mg/m2 IV (provided by Janssen–Cilag B.V.,
Beerse, Belgium) was given once every 2 weeks, for 2 years,
starting between 6 and 12 weeks after transplantation. If
bortezomib was not started within 12 weeks after ASCT, the
patient went off protocol. Bortezomib maintenance had to be
stopped after progression or relapse and when bortezomib
maintenance was interrupted for more than 6 weeks. Before
each bortezomib dose, the patient was evaluated for possible
toxicities. Bortezomib should be withheld in case of febrile
neutropenia until resolution of that condition, grade 4
haematological toxicity until sufficient recovery (haemoglo-
bin >7·0 g/dl, neutrophils >0·5 9 109/l, and platelet count
>50 9 109/l) and grade ≥3 non‐hematological toxicity until
the toxicity recovered to at least grade 2. After (partial) reso-
lution, the doses had to be adjusted. If the toxicity did not
resolve after dosing had been withheld for 2 weeks, the
patient discontinued treatment. Neuropathic pain and/or
peripheral sensory neuropathy had to be managed following
specific guidelines.
All patients provided written informed consent. The study
was approved by the ethical committee of Erasmus MC Rot-
terdam and the participating sites, and was conducted in
accordance with the Declaration of Helsinki. The trial is reg-
istered at the Dutch Trial Registry (www.trialregister.nl, no.
NTR1772).
Statistical analysis and definition of endpoints
This study was explorative as to the effect of bortezomib
maintenance. The induction regimen was changed in two
ways compared to our previous regimen. To get an indica-
tion if, in addition, bortezomib maintenance could be of any
benefit, it was decided to have a control arm without main-
tenance. The aim was to continue to a randomised phase III
study if it was feasible and showed an indication of a possi-
ble effect, within the limitations of a phase II study. The tar-
get number of patients to be randomised was 60, requiring
an estimated 90 primary registered patients. However, after
registration of 70 patients, only 44% were randomised.
Therefore, the target number of patients to be registered was
increased to 135 eligible patients.
The primary endpoint was EFS from randomisation (ap-
plied to all eligible randomised patients), defined as the time
from randomisation to failure or death from any cause,
whichever comes first. OS was defined as the time from reg-
istration until death from any cause. Patients still alive at the
date of last contact were censored. Failure was defined as
either no response on treatment or relapse; PR was not
defined as failure.
For the efficacy of the maintenance treatment, EFS (pri-
mary endpoint of this study) and OS were calculated with
the method of Kaplan–Meier. The median and probabilities
at 2 years were calculated together with 95% confidence
intervals. The safety of bortezomib maintenance was evalu-
ated by tabulation of the (serious) adverse events, coded
according to the NCI Common Terminology Criteria for
Adverse Events, CTCAE version 3.0.
Cox regression analysis and the associated likelihood ratio
test were used to test for trends with continuous or ordinal
variables. P‐values < 0.05 were considered significant.
Results
Patient characteristics
Between October 2007 and March 2012, 140 patients with a
median age of 57 (range 34–66) were included. The patient
characteristics are presented in Table 1. The majority of the
patients were male (78%) and patients presented generally
with stage IV disease (86%). Central pathology review was
performed in 136/140 registered patients. A diagnosis of
CD20 and CyclinD1 positive MCL could be confirmed in
131 cases. In three cases a diagnosis of another B‐cell lym-
phoma class was made (B‐CLL, NMZL, multiple myeloma),
and in two cases material was considered insufficient for a
classifying diagnosis. These five patients were considered inel-
igible in hindsight and excluded from analysis. MIB1 quan-
tification was performed in 87/131 MCL cases confirmed at
review with 25/87 (28,7%) with a MIB1 index ≥30%. In 114/
131 confirmed MCL, SOX11 was performed, of which four
were negative. Of these, however, two cases had either blas-
toid morphology or P53 protein expression both with high
MIB1 indices. A low MIPI score (Hoster et al., 2008) was
present in 57% of the patients.
Induction treatment and ASCT
The consort diagram is presented in Fig. 1. Out of 135 eligi-
ble patients at registration, 134 received all three R‐CHOP
cycles and 127 patients received both HD‐Ara‐C cycles.
Response evaluation showed that 79 patients (63%) achieved
a CR/CRu and 39 patients (31%) a PR. Three patients had
stable disease, two patients had PD and, in four patients,
response at this point was unknown. 115 patients proceeded
to ASCT (Fig. 1). Reasons for not proceeding to ASCT were
insufficient response (n = 6), insufficient stem cell harvest
(n = 3) or other reasons (n = 3). The response after BEAM
and ASCT improved: 99 patients (86%) achieved a CR/CRu
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and 15 patients (13%) a PR. One patient was not restaged. A
median of three (0–19) platelet transfusions and a median of
three (0–16) red blood cell transfusions were given. The
median time to white blood cell recovery >0·5 9 109/l was
25 days (16–139); the median recovery time to platelets
>50 9 109/l was 27 days (17–632).
Maintenance randomisation after ASCT
After ASCT, 62 of 115 transplanted patients were randomised
for bortezomib (n = 31) or no further treatment (n = 31).
After randomisation, one patient in each arm was found
ineligible, therefore, 30 patients in each study arm were anal-
ysed for the maintenance phase. Of 53 patients who were not
randomised, the majority were excluded according to proto-
col (insufficient bone marrow/haematological recovery, espe-
cially low platelet count) and refusal (Fig. 1). The
characteristics of the randomised patients were well‐balanced
between both arms, apart from the MIPI score, with fewer
patients with a low MIPI score in the bortezomib arm (50%
vs. 70%) (Table 1).
Outcome
With a median follow‐up of 77·5 months for all patients
alive, the EFS at 5 years was 51%, and the OS 73% (Fig. 2).
Thirty‐seven percent of patients (n = 50) died. Causes of
death were MCL (n = 26, 52%), treatment‐related (n = 1,
2%), intercurrent disease (n = 5, 10%), secondary malig-
nancy (n = 4, 8%), unknown (n = 4, 8%) and other
(n = 10, 20%). Seven of these last 10 patients died of com-
plications from allogeneic stem cell transplantation.
The median follow‐up of the randomised patients still
alive was 71·5 months. The EFS at 2 years was 83% in the
bortezomib arm (95% CI 65–93%), and in the patients with-
out maintenance 80% (95% CI 61–90%). The EFS at 5 years
was also similar in both arms, with 63% (95% CI 44–78%;
P = 0·73) in the patients treated with bortezomib versus 60%
(95% CI 40–75%) for the patients without maintenance
treatment (Fig. 3). The 5‐year OS was identical with 90%
(95% CI 72–97%) in both arms.
Toxicity of bortezomib maintenance
A planned interim analysis was performed in October 2011,
based upon data from 2 9 15 randomised patients with a
follow‐up of at least 3 months after randomisation. No unex-
pected toxicity was observed and it was decided to continue
enrolment as planned.
The median duration of maintenance therapy was
21 months. Out of 30 patients randomised to bortezomib
maintenance therapy, 15 continued the bortezomib therapy
Table 1. Baseline patient and disease characteristics.
All patients n = 135
Randomised patients after ASCT
No further treatment n = 30 Bortezomib maintenance n = 30
Age (median; range) 57 (34–66) 54 (36–65) 56 (34–66)
Male sex 78% 77% 80%
WHO performance
WHO 0 105 (78%) 25 (83%) 25 (83%)
WHO 1 60 (19%) 5 (17%) 4 (13%)
WHO 2 5 (4%) 1 (3%)
Ann Arbor stage
II 11 (8%) 1 (3%) 3 (10%)
III 8 (6%) 2 (7%) 2 (7%)
IV 116 (86%) 27 (90%) 25 (83%)
MIPI score
Low 77 (57%) 21 (70%) 15 (50%)
Intermediate 43 (32%) 6 (20%) 11 (37%)
High 13 (10%) 3 (10%) 3 (10%)
Unknown 2 (1%) 1 (3%)
Bone marrow
involvement
112 (83%) 26 (87%) 24 (80%)
MIB1 <30% 62 (46%) 11 (37%) 17 (57%)
≥30% 25 (18%) 8 (26%) 5 (17%)
unknown 48 (36%) 11 (37%) 8 (26%)
P53 <50% 68 (50%) 17 (57%) 18 (60%)
≥50% 7 (5%) 1 (3%) 0 (0%)
unknown 60 (45%) 12 (40%) 12 (40%)
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Figure 1. Consort diagram of all patients.
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for the planned 24 months, while 15 patients received borte-
zomib treatment for a median of 14 months (range 0–23).
The reasons to stop early were progressive disease (n = 4),
excessive toxicity (n = 6), refusal to start (n = 2) or continue
after the first dose (n = 1), second malignancy (n = 1) and
unknown (n = 1). Neurological adverse events grade 2 were
observed in four patients and grade 3 in one patient; no
grade 4 neurological adverse events were observed.
Secondary malignancy
Fifteen patients (11%) developed a secondary malignancy; six
of these had received bortezomib maintenance. They devel-
oped non‐melanoma skin cancer (n = 2), melanoma (n = 1),
prostate cancer (n = 1), oropharynx carcinoma (n = 1) and
neuro‐endocrine carcinoma (n = 1).
In the observation arm, nine patients developed a sec-
ondary malignancy [non‐melanoma skin cancer (n = 4), ade-
nocarcinoma (n = 3) and lung cancer (n = 2)].
Discussion
This phase II randomised trial (HOVON 75) was designed
upon the basis of the earlier HOVON 45 study (van’t Veer
et al., 2009). We aimed at improvement in outcome by con-
tinuing treatment of all patients after R‐CHOP with high‐
dose ARA‐C, irrespective of response, and by giving two
cycles of ARA‐C instead of one. Responding patients would
continue to ASCT. The outcome of the present study com-
pares favourably to the previous study. Therefore, these
interventions seem worthwhile. In the HOVON 45 study,
70% of the patients could be transplanted compared to 85%
in the current study. In the previous control study, a 4‐yearFigure 2. Event‐free survival and overall survival of all 135 patients.
Figure 3. Event‐free survival of randomised
patients.
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failure‐free survival of 36% and OS of 66% were achieved; in
the current HOVON 75 study, the EFS at 5 years was 51%,
and the OS 73%. This suggests an important role of cytara-
bine in the induction treatment of MCL, as reported in other
studies (Geisler et al., 2008;Hermine et al., 2016).
A second aim of our study was to investigate if borte-
zomib maintenance after ASCT would be feasible and could
improve outcome. This approach was new at the time. To
this end, we decided to have a parallel control arm without
maintenance. Bortezomib maintenance was feasible, although
the number of patients that could be randomised was lower
than expected due to insufficient recovery of the blood
counts after ASCT. Our study did not show any difference in
EFS.
This trial had a few limitations. Compared to the regimen
we used before (HOVON 45) we changed the protocol on
three points, so it is not clear which of the interventions
resulted in the observed better outcome. The study encoun-
tered unexpected difficulties in that many patients did not
reach the pre‐specified platelet count of >80 9 109/l before
week 12 after ASCT, resulting in a lower than expected num-
ber of patients to be randomised. The protocol therefore was
amended to increase sample size of patients registered in the
study. Finally, the small number of patients randomised
(phase II design) resulted in a relatively low statistical power
and the chance of missing a positive effect. However, the
completely overlapping curves suggest that bortezomib
monotherapy does not have a benefit in the context of main-
tenance. Therefore, there is no indication to initiate a phase
III study.
Bortezomib maintenance in MCL patients has also been
studied by the CALGB. In this randomised phase II study
(50403), bortezomib maintenance (bortezomib 1·6 mg/m2
weekly 4 of 8 weeks for 18 months), was compared with a
consolidation scheme (bortezomib 1·3 mg/m2 days 1, 4, 8
and 11 of a 3 week cycle for four cycles) after ASCT. Both
bortezomib arms performed equally at 5 years, showing PFS
of 70% vs. 69%, respectively. The authors compared these
results with those from their previous study without mainte-
nance or consolidation (59909), which demonstrated a 5‐year
PFS of 51%. They suggest a benefit from bortezomib consoli-
dation or maintenance (Kaplan et al., 2015). However, cau-
tion should be applied in comparing these studies, as the
50403 study did not have a direct control arm without borte-
zomib. We conclude, therefore, that there are still no strong
data to support the use of bortezomib maintenance after
ASCT in MCL.
At the time our study was designed, there was no scientific
evidence to support the added value of maintenance therapy
after ASCT. In contrast, rituximab maintenance until pro-
gression resulted in an impressive improvement (hazard ratio
0·55) of PFS and even OS in elderly MCL patients after
induction therapy with R‐CHOP (Kluin‐Nelemans et al.,
2012). Since then, rituximab maintenance is considered stan-
dard therapy for elderly patients (Dreyling et al., 2014).
Meanwhile, two different approaches were developed for
treatment of young MCL patients after ASCT. First, the Nor-
dic group prospectively assessed minimal residual disease
(MRD) in patients treated in the MCL2 trial (Andersen
et al., 2009). For those patients who developed a molecular
relapse after ASCT, pre‐emptive treatment with rituximab
was initiated (four weekly administrations of 375 mg/m2).
The large majority (92%) converted to molecular remission
again, but remission‐free survival curves did not show a pla-
teau, indicating that additional rounds of rituximab or other
therapies are needed. The authors stressed that any mainte-
nance therapy should have a duration of more than 2 years,
as the mean interval of molecular relapse after transplanta-
tion in their study was 18·5 months, with patients relapsing
even after 6 years (Andersen et al., 2009). In a long‐term fol-
low‐up it was shown that patients who have a late (>1 year
post‐ASCT) molecular relapse did well, whereas patients with
short (<1 year from transplant) molecular response duration
also had a short clinical response duration (Geisler et al.,
2012).
The second successful approach to improve the remission
duration after ASCT was described by the French LyMA
group (Le Gouill et al., 2017). In this randomised phase III
trial, patients received rituximab every 2 months for 3 years
or no further treatment. Rituximab significantly improved
both the PFS (83% at 4 years vs. 64%) and the OS (89% vs.
80%). In an ongoing study (MCL0208), the Italian FIL group
is investigating the role of maintenance with lenalidomide
for the same group of younger post‐ASCT patients.
Lenalidomide has been linked with the occurrence of sec-
ond primary malignancies (Dimopoulos et al., 2012). In our
study, in which no lenalidomide was given, we observed 15
cases, of whom six had received bortezomib.
Since the design of our study, other groups have published
results of other induction regimens. The European Mantle
Cell Lymphoma Network performed a large randomised trial
comparing a regimen with high‐dose ARA‐C, that is, alter-
nating R‐CHOP with R‐DHAP with R‐CHOP only (Hermine
et al., 2016). The response rate was 94% vs. 90% respectively,
and the CR/CRu rate was 55% vs. 39%. The LyMA group
used four cycles of R‐DHAP before ASCT, which resulted in
a response rate of 94% and 77% CR/CRu. (Le Gouill et al.,
2017). Finally, the Nordic MCL2 trial should be mentioned,
which used for induction rituximab with augmented CHOP
(maxi‐CHOP) followed by ASCT after conditioning with
BEAM or BEAC. An updated follow‐up of more than
6·5 years showed a median OS and remission duration of
longer than 10 years and a median event‐free survival of
7·4 years (Geisler et al., 2012).
Currently, a large randomised study of the European
Mantle Cell Lymphoma Network is examining the role of
ibrutinib in upfront therapy of transplant eligible patients.
The basis of induction treatment is the alternating R‐CHOP/
R‐DHAP regimen. This is the only induction regimen that
has proved to be superior in a randomised study.
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In conclusion, although the outcome of young patients
with MCL is still improving, the absence of a plateau in the
EFS after induction therapy, including ASCT, demands both
improvements in the induction therapy and interventions
thereafter. Our study confirmed the important role of ARA‐
C in the induction of young MCL patients. There was no
indication that bortezomib maintenance after ASCT may
improve outcome of MCL patients after ASCT. Other
options, especially BTK inhibitors such as ibrutinib, may be
explored to reduce relapse after ASCT.
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